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TanzaniaTen crude extracts and their solvent partition fractions from ﬁve species of Terminalia collected in Tanzania were
assessed for antimycobacterial effects usingMycobacterium smegmatis ATCC 14468 as a model organism.We re-
port here, for the ﬁrst time, on antimycobacterial effects of root and stem bark extracts of Terminalia sambesiaca
and Terminalia kaiserana as well as of fruit extracts of Terminalia stenostachya and leaf extracts of Terminalia
spinosa. T. sambesiaca gave the best effects of all the investigated species in terms of the sizes of the inhibitory
zones of root and stem bark extracts. A crude methanol root extract of T. sambesiaca gave lower MIC values
(1250 μg/ml) than its aqueous and butanol soluble fractions (MIC 2500 μg/ml). Our preliminary HPLC–DAD
data indicates that methanol and aqueous extracts of T. sambesiaca roots are rich in ellagitannins and ellagic
acid glycosides. Particularly, one polar ellagitannin at tR 10.3–10.9 min dominates the extracts quantitatively
and thus may be responsible for their good antimycobacterial effects. In contrast to the more polar fractions, a
chloroform soluble fraction of the roots of T. sambesiaca was devoid of antimycobacterial activity. Also crude
methanol and aqueous extracts of the stem bark of T. sambesiaca gave promising antimycobacterial effects (MIC
1250 μg/ml). All fractions of T. kaiserana roots, except from the aqueous insoluble gave good antimycobacterial
effects (MIC 1250μg/ml) and the aqueous extract showed the best effects of the fractions in terms of the size of in-
hibition zones. These results justify the uses of hot water decoctions of the roots of T. kaiserana for treatment of
cough, one of the symptoms of TB. According to HPLC–DAD data methanol extracts of T. kaiserana roots and their
aqueous fractions are rich in polar ellagitannins and ellagic acid glycosides. Quantitatively, the ellagitannins
dominate these extracts and therefore the good antimycobacterial activity of themethanol and aqueous extracts
is assumed to be due to these compounds. Sephadex LH-20 CC fractions of a methanol extract of the roots of
T. kaiserana inhibited the growth ofM. smegmatis, giving MIC values of 1000μg/ml. Ellagic acid glycosides in
these fractions must be responsible for their good antimycobacterial effects since they are present in high
concentrations. Good antimycobacterial effects were also obtained with a root extract of Terminalia sericea,
and especially the butanol soluble fraction was a good inhibitor of the growth ofM. smegmatis (MIC 1562 μg/ml).
Our preliminary HPLC–DAD results show that the roots of T. sericea are rich in ellagitannins, ellagic acid glycosides
and at least one stilbene compound. Extracts of the fruits of T. stenostachya gave good antimycobacterial effects,
butanol extracts being the most active. Also the leaves of T. stenostachya, and especially the butanol soluble ex-
tracts, give good antimycobacterial effects. Our HPLC–DAD data indicate that T. stenostachya leaves contain large
quantities of gallic acid, ellagitannins and ellagic acid glycosides. Our results indicate that many of the investigated
species of Terminaliamight contain leads for development of anti-TB drugs. Standardized extracts of T. sambesiaca,
T. kaiserana and T. sericea roots could be used as easily available and cheapmedicines for treatment of TB in remote
regions of East and South Africa.
© 2013 SAAB. Published by Elsevier B.V. All rights reserved.of Pharmaceutical Biology, Viikki
E, 00014, Finland. Tel.: +358 9
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y Elsevier B.V. All rights reserved.1. Introduction
Tuberculosis (TB) is historically one of the oldest and most wide-
spread diseases in history (McKinney, 2000). In recent years TB has
reemerged as a major disease of global importance (Pereira et al.,
2005). It is estimated that roughly one third of the world's population,
around 1.6–2 billion people are infected with TB and of these around
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Each year there are approximately three million deaths due to TB and
thusMycobacterium tuberculosis is responsible for more humanmortal-
ities than any other singlemicrobial species (Corbett et al., 2003; Rogoza
et al., 2011). In 2009 most of the cases of tuberculosis were assigned to
South-East Asia, Africa andWestern Paciﬁc regions, and 30% of the new
cases were found in Africa (World Health Organization, 2010). In Africa
as well as in Eastern Europe, TB deaths are increasing after almost 40
years of decline. The increase in new cases of TB has been considered
partly as a result of the AIDS pandemic making an increasing number
of individuals susceptible to the infection, but also due to the emergence
of strains resistant to available antibiotics (Ballell et al., 2005). Further-
more, TB is a disease which affects especially women and young people
in developing countries, partly due to poverty and therefore poor access
to medicines and treatment, as well as to late presentation of the illness
leading to poor prognosis (Connolly andNunn, 1996;Mann et al., 2008).
During the last couple of decades the HIV-related TB cases have in-
creased in Africa and especially in the sub-Saharan regions (Asres
et al., 2001) accounting for 80% of all HIV-related TB cases globally
(World Health Organization, 2010). According to an estimate made by
the World Health Organization the average incidence of tuberculosis
in African countries more than doubled between 1990 and 2005
(Chaisson andMartinson, 2008). In 2005, theWHOdeclared a TB emer-
gency situation in Africa. For example in Ethiopia TB is labeled as one of
the major causes of death with 15,700 new cases of infections appearing
in 1997 (World Health Organization, 1999). In Tanzania the number of
TB cases has steadily increased between 1983 and 2000, mainly
due to HIV/AIDS (Egwaga, 2003). South Africa is among the four
countries having the largest number of multi-drug resistant TB
(MDR-TB) and extensively drug-resistant TB (XDR-TB) (World Health
Organization, 2010). The currently available antituberculosis agents,
rifampicin and isoniazid, have serious limitations and infections
caused by resistant strains of M. tuberculosis are estimated to result
in up to 91% mortality among AIDS patients (Asres et al., 2001).
Moreover, many of the standard antituberculosis agents cause ad-
verse side effects in the human organism. The need for ﬁnding new
and more efﬁcient low-toxic antituberculosis agents is therefore urgent
(Rogoza et al., 2011). However, due to the predominance of TB in the de-
veloping world there has for long been a lack of economic incentive for
development of new anti-TB drugs. Recently, there has been a renewed
interest in ﬁnding new agents for treatment of TB (Global Alliance for
TB Drug development, 2001; Pauli et al., 2005; Rogoza et al., 2011).
Antimycobacterial active compounds have been found among many dif-
ferent chemical structures in higher plants (Mitscher and Baker, 1998).
Especially tropical plants are rich in useful secondary compounds and
new antitubercular agents which might act on other sites than the con-
ventional antibiotics. TB drugs might be found from medicinal plants
used in traditional medicine for treatment of tuberculosis and other
bacterial infections. The inﬂuence of herbal (traditional) medicine and
natural products upon drug discovery has been profound, with a number
of clinically active drugs derived from natural products or having a
natural product pharmacophore (Koehn and Carter, 2005).
In Africa the genus Terminalia (Combretaceae) comprises about thirty
species (Wickens, 1973) of small, medium or large trees, occurring in
Miombo and dry woodlands as well as rainforests. Studies on the
ethnopharmacological uses as well as on biological activities on extracts
of some African Terminalia species indicate that they could have
promising medical applications for treatment of infectious diseases,
both as standardized crude extracts (phytomedicines) and as sources
of (new) active compounds. Some compounds with antibacterial
activities have been isolated from African species of Terminalia. Anti-
bacterial resveratrol-3-β-rutinoside (Joseph et al., 2007), anolignan
B, termilignan B and arjunic acid (Eldeen et al., 2005, 2008) have
been isolated from the roots and stem bark of Terminalia sericea.
Ellagitannins (Conrad et al., 2001; Silva et al., 2000, 2002) and
pentacyclic triterpenoids (Conrad et al., 1998) with antibacterial effectswere isolated from the stem bark, roots and leaves of the West African
species Terminalia macroptera.
Just a small number of the thirty African species of Terminalia have
been investigated for growth inhibitory effects against mycobacteria.
In most cases crude extracts have been used for the screenings, and
just in a few cases some active principles have been isolated and charac-
terized. Methylated ellagic acid derivates from the stem bark of the
West-African species Terminalia superbawere found to give good growth
inhibitory effects against M. tuberculosis and Mycobacterium smegmatis
(Kuete et al., 2010). Acetone extracts of the stem bark of T. sericea have
been found to effectively inhibit the growth of M. tuberculosis H37 Ra as
well as the growth of a clinical strain of M. tuberculosis, but the active
compounds were not investigated (Green et al., 2010). The bark and
root extracts of Terminalia glaucescens were found to give some activity
against Mycobacterium ulcerans (Yemoa et al., 2011). Extracts of the
leaves, stem bark and roots of Terminalia stenostachya and the roots
and stem bark of T. glaucescens have been found to give promising
growth inhibitory activity against Mycobacterium madagascariense
and Mycobacterium indicus (Mbawambo et al., 2011) but the active
compounds in these species are still unknown. Crude extracts of the
leaves of T. glaucescens have shown growth inhibitory effects against
M. tuberculosis (H37Rv) giving MIC values of 1300 μg/ml (Nvau et al.,
2011). Hexane extracts of Terminalia avicennoides were found to give
very promising effects againstM. tuberculosis and Mycobacterium bovis
showing MIC values of 78 μg/ml (Mann et al., 2008). Later, the
pentacyclic triterpenoid, friedelin was isolated from a hexane fraction
of T. avicennoides roots and showed promising antimycobacterial effects
against M. bovis (Mann et al., 2011). These investigations demonstrate
that the genus Terminalia includes species showing promising
antimycobacterial potential and that the active compounds in these
plants should be investigated.
The aim of the present studywas to investigate the antimycobacterial
potential of Terminalia sambesiaca, T. kaiserana, T. spinosa, T. stenostachya
and T. sericea. Focus was put on root and stem bark extracts since these
plant organs are often used as hot water decoctions for treatment of in-
fectious diseases in African traditional medicine, but in some cases leaf
and fruit extracts were investigated. For example, the dried fruits of T.
sericea are used in a multi-component medication for treatment of TB
inMalawi (Msonthi and Mgombo, 1983), but due to the lack of fruit ma-
terial of T. sericea we investigated fruit extracts of the closely related T.
stenostachya for their antimycobacterial potential. The species of
Terminalia were selected on the basis of their traditional uses for treat-
ment of bacterial infections/TB (Kokwaro, 1976; Msonthi and Mgombo,
1983; Chhabra et al., 1989; Fyhrquist et al., 2002) and due to criteria of
not or only to a limited extent being investigated before for
antimycobacterial activity. The species of Terminalia used in this study
were collected in Tanzania in spring 1999 and are typical for East and
South Africa. The occurrence of T. kaiserana is restricted to East Africa,
and this might be the reason for why this species of Terminalia has not
been studied before for its antimycobacterial effects. Crude methanol
extracts giving good antimycobacterial activity were fractionated by
solvent partition in order to ﬁnd fractions giving high antimycobacterial
activity. Our study also focused on HPLC–UV–DAD proﬁling of the
antimycobacterially most potent extracts of Terminalia. The species
chosen for this study have given good to excellent antibacterial and
antifungal effects in our previous studies (Fyhrquist et al., 2002,
2004) and therefore we assumed to ﬁnd species of Terminalia giving
good antimycobacterial activity as well.
Due to the slow growth rate and the virulence ofM. tuberculosiswe
used the more rapidly growing saprophytic speciesM. smegmatis ATCC
14468 as a surrogate screen for testing the antimycobacterial effects of
extracts, solvent partition and column chromatography fractions of
Terminalia spp. The drug sensitivity of M. smegmatis is very close to
that of M. tuberculosis and thus screenings against this mycobacterial
species give predictive results for indicating anti-tuberculosis activity
(Newton et al., 2002).
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2.1. Plant material
The plant species were collected from Mbeya and Iringa districts
in Tanzania in February–March 1999. A voucher specimen is depos-
ited in the Botanical Museum (H) of the Finnish Museum of Natural
History in Helsinki, Finland and at the Herbarium of the University of
Dar-es-Salaam, Tanzania. Details of the species of Terminalia used in
this investigation and information on their uses in African traditional
medicine aswell as results on their antimycobacterial and antimicrobial
activities and isolated compounds are summarized in Table 1.
2.2. Extraction
2.2.1. Soxhlet extraction of the plant material
20g shade dried and ﬁnely milled plant material (roots, stem bark,
leaves and fruits)was extractedwith 500mlMeOH in a Soxhlet appara-
tus for 4h. The resulting extract was reduced to dryness under vacuum
at +40°C using a rotary evaporator. The extract was then freeze-dried
in a lyophilisator for 1–2days. The resulting residue was redissolved in
MeOH (50mg/ml) for antimycobacterial testing.
2.2.2. Solvent fractionation
1500mg lyophilized crude Soxhlet MeOH extracts of different plant
organs of the Terminalia species were dissolved in 50mlwater for 30min,
half of which in an ultrasonic bath. The extracts were centrifuged and the
aqueouspartwas used for further fractionation;ﬁrstwith 3×25mlCHCl3:
EtOH (2:1) and then with 3×25ml n-BuOH, resulting in CHCl3, n-BuOH,
aqueous and aqueous-insoluble fractions. The fractions were evaporated
to dryness and re-dissolved in MeOH to stock solutions of 50mg/ml for
antimycobacterial testing.
2.3. Acid-butanol assay for determining proanthocyanidins in root extracts
of T. kaiserana and T. sambesiaca
Acid hydrolysis for indication of condensed tannins (proxantho-
cyanidins) to yield red anthocyanidines was performed according to
Hagerman (2002). 20 mg of dried methanolic extracts of the roots
of T. kaiserana and T. sambesiacawere dissolved in 1ml MeOH. The ex-
tractswere diluted 1:9 so that the ﬁnal concentrationwas 2mg/ml. 1ml
of these extractswere hydrolyzed using 6ml acid butanol reagent (5% v/v
conc. HCl in n-butanol) and 250 μl iron reagent (2% w/v ferric am-
monium sulfate in 2 M HCl). Hydrolysis was performed in boiling
water bath for 45min. Tubes were cooled and absorbance was measured
at 550nm.
2.4. Chromatography and mass spectrometry
2.4.1. TLC method for catechins and oligomeric proanthocyanidins in
T. sericea roots
A TLCmethod according to Vovk et al. (2002) was used. Glass-backed
cellulose plates (Merck, Art. 5716) pre-developed with water were used.
10μl of the aqueous,water-insoluble and BuOH fractions of T. sericea roots
(10 mg/ml) were applied as a thin line at the base of the plate using
Linomat. The extracts were applied 2× so that the ﬁnal volume was 20
μl. 10 μl of gallocatechins, catechins and epicatechins (Sigma-Aldrich, 1
mg/ml) were used as standards. The plates were dried with a hair dryer
and were put in a horizontal TLC chamber. The plates were developed
in 1-butanol+water+acetic acid, 4+2+1 (v/v). Development distance
was 5cm. The platewas then dipped in vanillin: H3PO4 solution and dried
carefully. The compounds of interest became visible as red spots. The Rf
values of compounds in the fractions and extracts of T. sericea were
compared to those of the standard compounds.2.4.2. TLC method for ellagitannins and gallic/ellagic acid in
Terminalia species
Aluminium-backed RP-18 F254s plates (Merck, Darmstadt, Germany)
were used for investigating more polar compounds, such as ellagitannins
and ellagic acid glycosides, in extracts of stem bark and roots of
T. sambesiaca, T. kaiserana and T. sericea. Sephadex LH-20 fractions
of the roots of T. kaiserana were also investigated by this method.
1 μl of extracts and solvent partition fractions (50 mg/ml) or 5 μl
Sephadex LH-20 fractions (20 mg/ml) were applied 1 cm from the
base of the plates with a microcapillary pipette. 1 μl of ellagic acid,
gallic acid and (+)-catechin (Merck, 1 mg/ml) were applied as stan-
dards. The plates were developed in distilled water + methanol +
orthophosphorous acid, 5+5+0.1 (v/v) and developed to a distance
of 8cm. The plates were documented using a Camaq Video documenta-
tion system and operated with Video store software. The plates were
photographed at 254 and 366 nm. Some of the plates were sprayed
with a solution of vanillin:sulfuric acid, developed in an oven at
+120 °C for 5min and observed for colored spots. The Rf values of the
compounds in the extracts were compared to those of the standards.
2.4.3. Sephadex LH-20 column chromatography
AMeOH root extract of T. kaiseranawas fractionated using Sephadex
LH-20 column chromatography. Sephadex LH-20 (Pharmacia, Uppsala)
was swollen in MeOH overnight before use. A glass column (40 cm in
length, 1.8 cm in diameter) was ﬁlled with a slurry of Sephadex LH-20.
650mg of the dry methanol extract of the roots of T. kaiseranawas ap-
plied to the column. Gradient elutionwas performed startingwith 100%
MeOH and continuing with MeOH:EtOH combinations increasing the
percentage of EtOH to 96% in the end of the fractionation. Nine fractions
were collected (20 ml of each) and pooled to four fractions following
analytical RP-18 thin layer chromatography: F1 (152mg), F2 (111mg),
F3 (25mg), and F4 (63mg).
2.4.4. HPLC–UV/DAD method I
HPLC analyses using the method of Dastmalchi et al. (2007) were
performed for qualitative analysis of extracts of Terminalia species. The
liquid chromatographic system (Waters 600 E) consisted of a pump and
a controller coupled to a 991 PDA detector and a 717 plus autosampler
under control of Millennium 2000 software (Waters Corp., Milford,
USA). Samples of 20 μl (20mg/ml in MeOH) were injected. Separations
were performed on a reversed phase Hypersil BDS-C-18 analytical
column (250mm×4.6mm ID 5 μm). Elution was performed as gradient
elution using A) 0.1% formic acid in water and B) 100% acetonitrile. The
gradient started with 85% A and ended with 100% B and the length of
the runswere 50–60min. Theﬂowratewas 1ml/min. UV chromatograms
were constructed at 254, 280 and 340nm. UVλ absorptionmaxima spec-
tra of the compounds of interest were recorded between 200 and 400nm
using Millennium 2000 software and compared to reference com-
pounds such as ellagic acid, gallic acid and epigallocatechin gallate
(Sigma-Aldrich).
2.4.5. HPLC–UV/DAD method II
Qualitative HPLC analyses were performed using a second HPLC-
method according to Julkunen-Tiitto et al. (1996), developed especially
for detection of polyphenols. HPLC-system consisted of a Waters 600 E
pump and a controller coupled to a 991 PDAdetector and an autosampler
under control of Agilent Chemstation software (Waters Corp., Milford,
USA). Samples of 10μl (2mg/ml in 50%MeOH)were injected. Separations
were performed on a reversed phase Hypersil Rp C-18 analytical column
(length: 10 mm; ID: 2 mm). Gradient elution was performed by using
solvent systems as follows: A) Aqueous 1.5% tetrahydrofuran + 0.25%
orthophosphoric acid and B) 100% MeOH. The ﬂow rate was 2ml/min.
UV chromatograms were constructed at 220, 270, 280, 320 and 360nm.
UVλ absorption maxima spectra of the compounds of interest were
recorded between 200 and 400nm using Agilent Chemstation software.
Table 1
Terminalia species collected in Tanzania and included in this study. Summary of traditional uses as well as antimicrobial/antimycobacterial effects and identiﬁed compounds of the species. Results obtained by our research group marked with an
asterisk *.
Terminalia species (collector voucher specimen) Uses of plant species in TM Way of preparation in TM Antibacterial,
antifungal and antimycobacterial effects
Identiﬁed compounds
T. sericea Burch ex. DC.
(P. Fyhrquist & L. Mwasumbi,
voucher 1697045)
Tuberculosis: In Malawi the
dried fruit is used in a
multi-component recipe
(Msonthi and Mgombo, 1983;
Moshi and Mbwambo, 2005).
Diarrhea, colic, pneumonia,
gonorrhea, cough, skin
diseases (Drummond and
Coates-Palgrave, 1973;
Hedberg et al., 1982).
In Tanzania: Diarrhea, fever,
hypertension, bacterial infections
(Fyhrquist et al., 2002).*
Dried fruit for tuberculosis,
but the way of preparation
not published (Msonthi and
Mgombo, 1983).
Hot water decoctions of roots
for diarrhea and colic as well
as for venereal diseases
(Neuwinger, 1996, 2000).
Outer layer of roots boiled in
hot water and decoction
drunk for pneumonia
(Drummond and
Coates-Palgrave, 1973).
In Tanzania roots, stem
bark and leaves made
into hot water decoctions
or mixed in maize porridge
to treat diarrhea, fever
and hypertension
(Fyhrquist et al., 2002). *
Leaf extracts antibacterial (Eloff, 1999;
Fyhrquist et al., 2002*).
Very promising antibacterial and
antifungal proﬁle of especially aqueous
and MeOH extracts of roots and stem
bark (Fyhrquist, 2002, 2004*; Innocent,
2002; Steenkamp et al., 2004; Moshi and
Mbwambo, 2005; Tshikalange et al., 2005;
Eldeen et al., 2005).
Resveratrol-3-O-β-
rutinoside exhibited a weak antibacterial
activity against E. coli (Joseph et al., 2007).
Ethanol, ethyl acetate and dichloromethane
root and bark extracts antimycobacterial
giving MICs of 1.56–3.12 mg/ml
(Eldeen and Van Staaden, 2007).
Acetone extracts of stem bark
antimycobacterial (MIC 25 μg/ml)
(Green et al., 2010).
The crude MeOH extract of the roots
and especially the BuOH fraction of this
extract inhibit effectively the growth
of M. smegmatis (Activity index compared
to rifampicin is 0.68; MIC 1.56 mg/ml). *
Triterpenes sericoside and arjunglucoside in roots and
stem bark (Bombardelli et al., 1974, 1974, 1986;
Maeda and Fukuda, 1996).
Resveratrol-3-O-β-D-rutinoside in roots
and stem bark (Bombardelli et al., 1975).
Antibacterial resveratrol-3-O-β-D-rutinoside, arjungenin,
stigmasterol and β-sitosterol in root
bark (Joseph et al., 2007).
Antibacterial anolignan B in ethylacetate extracts
of roots (Eldeen et al., 2005).
Antibacterial Termilignan B and arjunic acid in roots
(Eldeen et al., 2008).
Antimicrobial compounds in leaves unknown.
Ellagic acid derivates, ellagitannins, gallic acid,
catechins and a stilbene in BuOH extracts of roots.*
T. sambesiaca Engl. & Diels.
(P. Fyhrquist & L. Mwasumbi,
voucher 1697061)
Bloody diarrhea, appendicitis,
stomach ulcers, cancer
(Chhabra et al., 1989).
Hot water decoctions
of stem bark and leaves
to treat cancer, stomach
ulcers and appendicitis,
powdered root bark
for bloody diarrhea
(Chhabra et al., 1989).
Promising antibacterial (Chhabra et al., 1989;
Fyhrquist et al., 2002*) and antifungal proﬁle
(Fyhrquist et al., 2004*; Masoko et al., 2005;
Shai et al., 2008) of MeOH extracts of the roots
and stem bark as well as acetone,
hexane and dichloromethane extracts of
the leaves.
May contain saponin-like compounds in the leaves
(Masoko et al., 2005; Masoko and Eloff, 2005).
Ellagic acid glycosides,
ellagitannins and gallic acid in methanol
extracts of roots and stem bark. *
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Terminalia species (collector voucher specimen)
Uses of plant species in TM Way of preparation in TM Antibacterial, antifungal and antimycobacterial effects Identiﬁed compounds
Gave the most promising antimycobacterial
results of the ﬁve species of Terminalia we
used for our investigation. Root and stem bark
crude (MIC 1.25 mg/ml)
and aqueous extracts (MIC 2.5 and 1.25 mg/ml)
gave activity indexes of 0.70–0.71
compared to rifampicin *.
T. kaiserana F. Hoffm.
(P. Fyhrquist & L. Mwasumbi,
voucher 1697066)
Gonorrhea, bilharzia,
scabies, headache, cough,
cardiac problems (Haerdi, 1964;
Kokwaro, 1976; Chhabra et al., 1989).
In Tanzania: diarrhea, gonorrhea
and vomiting (Fyhrquist et al., 2002).*
Hot water decoctions
of the roots are used
for headache, cough,
backache, gonorrhea,
bilharzias and as diuretics
(Haerdi, 1964; Kokwaro,
1976; Chhabra et al., 1989).
In Tanzania dried leaves,
roots or stem bark are made
into hot water decoctions and
tea or mixed with Ugali for
diarrhea,
gonorrhea and vomiting
(Fyhrquist et al., 2002).*
Promising antibacterial and antifungal proﬁle
(Fyhrquist et al., 2002, 2004). To the best of our
knowledge there are no other reports on the
antimicrobial effects of extracts/
compounds of this
species despite of its frequent use in traditional
medicine in East Africa. *
Cytotoxic in brine shrimp test (Moshi etal., 2006).
Especially the aqueous part as well as the crude
MeOH extract of roots, both enriched in polar
ellagitannins, are active against M. smegmatis
(MIC 1.25 mg/ml). Ellagic acid glycoside rich
Sephadex LH-20 fractions gave promising
antimycobacterial effects (MIC 1 mg/ml). *
Ellagitannins, ellagic acid glycosides,
gallotannins and gallic acid as well as
condensed tannins in roots. *
T. stenostachya Engl. & Diels.
(P. Fyhrquist & L. Mwasumbi,
voucher 1697028)
For treatment of epilepsy and poisoning
(Gelﬂand et al., 1985; Neuwinger, 2000).
Root decoctions for
epilepsy/poisoning
(Gelﬂand et al., 1985;
Neuwinger, 2000)
Extracts of stem bark and leaves have
given good antibacterial (Fyhrquist et al., 2002)
and antifungal (Fyhrquist et al., 2004) results*.
Stem bark, root and leaf extracts of this species
effectively inhibited the growth of Mycobacterium
madagascariense and M. indicus, as well as the
growth of some gram-negative and gram-
positive bacteria (Mbawambo et al., 2011).
BuOH fractions of extracts of leaves and fruits
active against M. smegmatis. *
Leaf extracts contain gallic acid in high
concentrations, ellagitannins, gallotannins
and ellagic acid glycosides. *
T. spinosa Engl.
(P. Fyhrquist & L. Mwasumbi,
voucher 1697047)
For treatment of malaria,
fever and wounds
(Kokwaro, 1976;
Heine and Brenzinger, 1988;
Chhabra et al., 1989)
Fresh leaves are pounded
and the juice drank for
malaria and stem bark is
chewed or added to tea
to reduce fever
(Heine and Brenzinger, 1988).
Good antibacterial activity of young branches on
S. aureus and Enterococci, but no inhibition of
Mycobacterium tuberculosum
growth (Fabry et al., 1998).
A BuOH fraction of a MeOH extract of the
leaves inhibited the growth of M. smegmatis. *
Tannins, coumarins (Okemo, 1996; Omulokoli, 1997)
Gallic acid, gallotannins, ellagitannins
and ellagic acid glycosides in the leaves. *
Plant uses for tuberculosis or its symptoms, such as cough marked with bold text. TM, traditional medicine.
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Table 2
Antimycobacterial effects of extracts and their solvent partition fractions of species of
Terminalia collected in Tanzania in spring 1999. Results obtained with an agar diffusion
methodA. * Activity index in relation to rifampicin.
Bacterial species M. smegmatis ATCC 14468 A.I.*
Terminalia species,
crude extracts and their fractions
T. sambesiaca R Cr 37.0 ± 0.5 0.70
T. sambesiaca WS 34.0 ± 0.5 0.65
T. sambesiaca BuOH 25.0 ± 1.3 0.48
T. sambesiaca WI 29.5 ± 1.0 0.56
T. sambesiaca CHCL3 NA NA
T. sambesiaca S Cr 26.0 ± 0.0 0.50
T. sambesiaca WS 37.5 ± 0.3 0.71
T. sambesiaca BuOH 34.5 ± 0.8 0.66
T. sambesiaca WI 22.0 ± 2.0 0.42
T. sambesiaca CHCL3 17.0 ± 0.0 0.32
T. stenostachya S Cr 14.0 ± 0.0 0.27
T. stenostachya WI NA NA
T. stenostachya Ws NA NA
T. stenostachya BuOH 17.5 ± 0.3 0.33
T. stenostachya CHCL3 17.0 ± 1.5 0.32
T. stenostachya F Cr 31.5 ± 0.5 0.60
T. stenostachya WS 27.0 ± 1.5 0.51
T. stenostachya WI 14.0 ± 0.0 0.27
T. stenostachya BuOH 35.5 ± 0.3 0.68
T. stenostachya L Cr 20.5 ± 1.2 0.39
T. stenostachya WI NA NA
T. stenostachya Ws 24.0 ± 0.0 0.46
T. stenostachya BuOH 25.0 ± 0.3 0.48
T. stenostachya CHCL3 14.0 ± 1.5 0.27
T. sericea R Cr 31.5 ± 0.3 0.60
T. sericea WS 27.0 ± 1.0 0.51
T. sericea WI 14.0 ± 0.0 0.27
T. sericea BuOH 35.5 ± 0.8 0.68
T. sericea CHCL3 * *
T. sericea L Cr 16.0 ± 0.5 0.30
T. sericea WS NA NA
T. sericea WI NA NA
T. sericea BuOH 17.0 ± 0.0 0.32
T. sericea CHCL3 16.5 ± 0.3 0.31
T. kaiserana R Cr 27.5 ± 3.5 0.52
T. kaiserana WI 14.0 ± 0.0 0.27
T. kaiserana Ws 25.0 ± 1.6 0.48
T. kaiserana BuOH 19.5 ± 2.0 0.37
T. kaiserana CHCL3 20.0 ± 0.0 0.38
T. kaiserana L Cr 18.0 ± 0.0 0.34
T. kaiserana WI NA NA
T. kaiserana BuOH 21.5 ± 0.5 0.41
T. kaiserana CHCL3 NA NA
T. spinosa L Cr 21.5 ± 0,3 0.41
T. spinosa WS 23.0 ± 1,0 0.44
T. spinosa WI NA NA
T. spinosa BuOH 22.5 ± 0.3 0.43
T. spinosa CHCL3 17.0 ± 0.0 0.32
Rifampicin 52.5 ± 0.5 100.00
*Crude extracts in MeOH; Cr, crude extract; R, roots; S, stem bark; F, fruits; L, leaves; WS,
aqueous fraction;WI,water insoluble fraction; BuOH, butanol fraction; CHCL3, chloroform
fraction; NA, not active. A Two hundred μl extracts/fractions (50 mg/ml) and rifampi-
cin (10 mg/ml) were applied on ﬁlter paper disks. Diameter of inhibition zones in mm
as mean of triplicates (n = 3) ± SEM of three experiments. Most promising results (IZ ≥
20mm) indicated by bold text. Activity index results obtained using disk diffusion data.
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2.5.1. Agar disk diffusion
Amodiﬁed agar disk diffusionmethod based on themethods of Barry
and Thornsberry (1991) and Rauha et al. (2000) was used.M. smegmatis
ATCC 14468 was grown for ﬁve days at +37 °C on Löwenstein–Jensen
agar slants (Becton–Dickinson & Company, USA). 200μl bacterial culture
containing 1.0×108CFU/ml was inoculated on Petri dishes (∅=14cm,
Bibby Sterilin, UK) containing 30 ml Middlebrook 7H10 agar (Difco)
supplemented with oleic acid, albumin, dextrose and catalase (OADC
supplement, Difco) as top layer and 30 ml Base agar (Difco) as base
layer. Filter paper disks (∅ = 12.7 mm, Schleicher & Schuell) loaded
with 200μl extracts/fractions (50mg/ml and 20mg/ml), 200μl rifampicin
(10mg/ml, Sigma-Aldrich) and 200 μl MeOH (as negative control) were
allowed drying completely before placing them equidistantly from each
other on the Petri dishes. Prior to incubation the dishes were kept in
+4 °C to facilitate diffusion of the extracts into the agar. The dishes
were then incubated at +37 °C for ﬁve days. Each extract/fraction was
tested in triplicate. The diameter of zones of inhibition (IZ)wasmeasured
with a caliper and the mean of 3 diameters ±SEM was calculated. For
estimating minimum inhibitory concentration (MIC) two-fold dilutions
of the extracts and fractions from 195 μg/ml to 25 mg/ml and from 78
μg/ml to 20mg/ml, respectively,were performed. For rifampicin dilutions
ranging from 2.44μg/ml to 5mg/ml were used. The MIC was considered
as the lowest concentration of extract, fraction or antibiotic giving a
small (1 mm) clear zone of growth inhibition around the disk. Activity
index of the plant extracts and fractions was measured in relation to
rifampicin according to Singariya et al. (2012).
AI Activity indexð Þ ¼ Inhibition zone of the plant extract
Inhibition zone of Rifampicin
:
2.5.2. Microplate dilution method for MIC estimations
A modiﬁed microplate assay based on Collins and Franzblau (1997)
was used for measuring minimum inhibitory concentrations of the
extracts and fractions of the most promising species of Terminalia.
M. smegmatis ATCC 14468 was grown for ﬁve days at +37 °C on
Löwenstein–Jensen agar slants. After completion of growth a small
amount of culture was transferred into Dubos broth and the absorbance
of the samples was measured at 625 nm. The absorbance at 625 nm
was adjusted to 0.1 (approx. 1.0×108CFU/ml) using Dubos broth supple-
mented with Dubos broth albumin (Difco). This suspension was diluted
further so that the ﬁnal number of cells in inoculum was 5.0 × 105
CFU/ml. A portion of 100 μl of inoculum was added to the wells of the
microplate (Nunc, Nunclone, Denmark). Dilutions of 100 μl of each of
the plant extracts (9.76μg/ml–5mg/ml in Dubos broth) and of rifampicin
(0.9 μg/ml–1 mg/ml in Dubos broth) were added to the wells of the
microplate, so that the ﬁnal volume/well was 200 μl. Thus, the ﬁnal
number of bacterial cells/well at starting point of experiment was
2.5×105CFU/ml. Wells containing all tested concentrations of plant ex-
tracts, fractions or rifampicin in broth without bacterial inoculum were
used as controls in order to measure background absorbance produced
by the extracts, fractions and the antibiotic. The solvent control; MeOH
at 5% or less did not affect the growth ofM. smegmatis. The plates sealed
with paraﬁlmwere incubated for four days at+37°C, whereafter turbid-
ity of the wells at 620nmwas measured using a Victor (Wallac, Finland)
spectrophotometer. The results were measured as mean percentage
inhibition of three replicate samples ±SEM. The minimum inhibitory
concentration (MIC) was considered as the smallest concentration of
the extracts/fractions as well as rifampicin inhibiting 90% or more of
the growth ofM. smegmatis.
3. Results and discussion
Altogether 48 extracts and solvent partition fractions of different
polarities from ﬁve species of Terminalia, some of them used fortreatment of tuberculosis or its symptoms in African traditionalmedicine
(Table 1), were screened for their growth inhibitory effects against
M. smegmatis ATCC 14468. M. smegmatis is an important test model
organism for the initial, primary screening for antimycobacterial
activity in the search for drugs with potential anti-tuberculosis
effects. Inhibitory effects against this bacterial strain indicate that the
extracts/fractions also to a certain extent inhibit the growth of the closely
related M. tuberculosis. M. smegmatis grows faster than Mycobacterium
tuberculosum and does not present the pathogenic properties of the
latter (Pauli et al., 2005; Carneiro et al., 2008). M. smegmatis has
been found to be rather resistant to rifampicin and it has been suggested
Table 3
Minimum inhibitory concentrations of antimycobacterially promising crudemethanol extracts of Terminalia species and their solvent partition fractions, as well as Sephadex-LH 20 fractions
of a root extract of Terminalia kaiserana againstMycobacterium smegmatis ATCC 14468. MIC values were obtained both using microdilution and agar diffusion methods.
Crude extracts and their solvent partition fractions as well as fractions obtained with Sephadex LH-20 MIC microdilution (μg/ml) MIC agar diffusion (μg/ml)
T. sambesiaca roots:
Crude methanol extract 1250 (IC99) 1562
Aqueous fraction 2500 (IC96) 3125
Aqueous-insoluble fraction 2500 (IC95) 3125
T. sambesiaca stem bark:
Crude methanol extract 1250 (IC98) 1562
Aqueous fraction 1250 (IC95) 1562
T. kaiserana roots:
Crude methanol extract 1250 (IC98) 3125
Aqueous fraction 1250 (IC99) 1562
Butanol soluble fraction 1250 (IC99) 1562
Chloroform soluble fraction 1250 (IC100) 1562
Sephadex LH-20 fractions of T. kaiserana rootsa:
F1 4000 (IC90) 5000
F2 1000 (IC94) 1250
F3 1000 (IC92) 1250
F4 1000 (IC91) 1250
T. sericea roots:
Crude * 3125
Butanol soluble fraction * 1562
Rifampicin 3.90 (IC98) 78
* Not tested due to lack of material.
a Fractions F1–F4 obtained with Sephadex LH-20 column chromatography from a methanol root extract of Terminalia kaiserana. In brackets the percentage of the bacterial cell growth
inhibited by indicated concentration. IC= inhibitory concentration.
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et al., 2000). Thus, good inhibitory results of plant extracts against this
species of Mycobacterium might indicate promising results againstFig. 1. HPLC proﬁle at 280 nm of a crude methanol extract of the roots of Terminalia sambesiaca
10.978, 12.415 and 15.357min show UV absorption spectra with three absorption maxima pea
glycosides occur at tR 18.3, 19.7, 20.6 and 21.5min.drug resistant strains of M. tuberculosis. Tables 2 and 3 present the re-
sults on antimycobacterial activity of extracts and fractions of the inves-
tigated species of Terminalia.obtained using the HPLC method II. The extract is rich in ellagitannins. Ellagitannins at tR
ks, typical for ellagitannins (the two ﬁrst mentioned demonstrated in ﬁgure). Ellagic acid
Fig. 2. HPLC proﬁle at 220 nm of an aqueous fraction of a MeOH extract of the roots of Terminalia sambesiaca. Obtained using the HPLC method II. This extract is enriched in polar
ellagitannins (tR= 4.4, 5.0, 6.3, 7.2, 8.8 and 10.3min) and thus these compounds could be responsible for the good antimycobacterial effects of this extract. UVλ absorption maxima of
the dominating ellagitannin in this extract, at tR 10.325min is illustrated in ﬁgure.
Fig. 3. Catechins and procyanidins in solvent partition fractions of a MeOH root extract of
Terminalia sericea separated by cellulose-thin layer chromatography (TLC). Standards and
fractions from the left to right: procyanidin B 1, procyanidin B 2, (+)-catechin, epicatechin,
gallocatechin, epigallocatechin, epicatechin-gallate, a mixture of catechins, aqueous frac-
tion of a root extract of T. sericea, aqueous-insoluble fraction, and a BuOH fraction.
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Although T. sambesiaca is not used for the treatment of tuberculosis
in African traditional medicine, this species gave the most promising
antimycobacterial effects of theﬁve species of Terminaliawe investigated,
in terms of sizes of inhibition zones. Both extracts of the roots and stem
bark effectively inhibited the growth ofM. smegmatis giving clear inhibi-
tion zones of 37.0 and 26.0mm for crude methanolic root and stem bark
extracts, respectively (Table 2). This is the ﬁrst time T. sambesiaca is
reported to give promising antimycobacterial effects. The roots contain
many antimycobacterial compounds of different polarities since both
the aqueous and the aqueous-insoluble fractions gave growth inhibi-
tion. MIC was 2500 μg/ml for the aqueous and aqueous-insoluble
fractions (Table 3) and diameters of inhibition zones were 34.0mm
and 29.5mm, respectively (Table 2). The crude methanol extracts of the
roots were even more effective than the fractions giving MIC values of
1250 μg/ml (Table 3). Some of the compounds in the crude extract
might act synergistically, enhancing the antimycobacterial effects of
each other. The antimycobacterial effects of the stembark of T. sambesiaca
were mainly concentrated to the more polar fractions, such as the aque-
ous and butanol soluble fractions giving inhibition zones of 37.5 and
34.5 mm, respectively (Table 2). Also the aqueous insoluble part of the
stem bark gave some antimycobacterial effects. Chloroform-soluble
fractions of the roots gave no antimycobacterial activity, whereas the
same fraction of the stem bark gave slight antimycobacterial activity.
The lipid-rich hydrophobic cell wall of mycobacteria makes them
generally more susceptible to less polar compounds. Thus, the more
polar compounds in the aqueous fraction and crude methanol extractsof T. sambesiaca might inhibit the growth of Mycobacterium with some
other mechanisms, not necessarily entering the cell.
Very little is known about the chemical composition of T. sambesiaca
apart from one investigation (Masoko et al., 2005) in which saponin-like
compoundswere found in the leaves, using TLC asmethod. To our knowl-
edge the chemical composition of the roots of T. sambesiaca has not been
investigated before. Our results obtained using the acid butanol assay
show that the roots of T. sambesiaca contain moderate amounts of
condensed tannins; 9.2 mg ± 0.008 mg g−1, mean ± SD. According
to our results obtained by HPLC–UV–DAD, root extracts of T. sambesiaca
contain gallic acid, ellagic acid glycosides and ellagitannins (Fig. 1).
Fig. 4. HPLC proﬁle obtained with the HPLC method II and recorded at 280 nm of a butanol fraction of the crude root extract of Terminalia sericea. This extract is rich in ellagitannins.
Figure shows UVλ absorption maxima spectra of an ellagitannin at tR 15.249min and a stilbene at tR 17.049min. Compound at tR 20.286min is an ellagic acid derivate.
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methanol extract of the roots, and is also present in high quantities in
the aqueous extract. This compound shows three UVλ absorption
maxima peaks, which is typical for ellagitannins, the absorption
maxima occurring at 217, 260 and 380 nm (Fig. 1). Compounds at
tR 9.840, 12.415 and 15.357min are also ellagitannins. Compound at tR
12.415min seems to be closely related to compound at tR 10.978 min,
and shows UVλ absorption maxima at 216, 257 and 382 nm (Fig. 1).
Ellagitannins occur in high quantities also in an aqueous fraction of the
crude root extract, which is enriched in polar ellagitannins (Fig. 2). This
means that theymust be readily extractable also in hot water decoctions,
theway this plant is used in African traditionalmedicine. The ellagitannin
at tR 10.3–10.9min, present in both the aqueous fraction and the crude
extract in high concentrations might partly be responsible for the
promising antimycobacterial effects of the aqueous and crude extracts.
Ellagitannins, such as punicalagin, punicalin, chebulanin, chebulagic
acid, chebulinic acid, corilagin, terﬂavin, terchebulin and tellimagrandin,
as well as some condensed tannins have been characterized from
Terminalia species (Burapadaja and Bunchoo, 1995; Silva et al., 2000;
Pfundstein et al., 2010). The co-occurrence of punicalagin, punicalin,
chebulinic and chebulagic acid seems to be a chemotaxonomic feature
of the genus Terminalia (Yoshida et al., 2010). Several authors have re-
ported that ellagitannins possess powerful antimicrobial effects: Corilagin
and tellimagrandin have been found to reduce the minimum inhibitory
concentration of β-lactams in methicillin-resistant Staphylococcus aureus
(Shiota et al., 2004) and to dose-dependently affect membrane per-
meability of Candida albicans and Escherichia coli, but not of S. aureus
(Li et al., 2012). Tannin rich extracts of Terminalia species have proved to
be effective inhibitors of the growth of the Gram-negative bacterium
Pseudomonas aeruginosa, showing resistance against many conventionalantibiotics (Elegami et al., 2002). Punicalagin showed potent growth
inhibitory effects against both Gram-negative and Gram-positive bacte-
ria (among them MRSA) as well as against fungi (Reddy et al., 2007).
Furthermore, ellagitannins have been found to act synergistically with
ampicillin against S. aureus and to inhibit growth of this bacterium by
causing lysis of the cell walls (Din et al., 2012). There exists only one
publication on the growth inhibitory effects of ellagitannins against
Mycobacteria, in which punicalagin was shown to be responsible for
the good antimycobacterial effects of a stem bark extract of Combretum
molle (Asres et al., 2001).
T. sambesiacahas several uses inAfrican traditionalmedicine, among
them for treatment of bloody diarrhea and stomach ulcers (Table 1;
Chhabra et al., 1989), but it has not been reported to be used for the
treatment of tuberculosis. Thus, our results indicate that hot water
decoctions of the roots and stem bark of this species could be used as
readily available and affordable treatment of tuberculosis in East and
South African rural regions. These decoctions contain ellagitannins and
ellagic acid derivates which may be the causative agents of the good
antimycobacterial effects we can demonstrate. T. sambesiaca roots and
stem bark are potential sources of new antimycobacterial ellagitannins
and ellagic acid glycosides, and research should be conducted on their
growth inhibitory effects on different strains ofM. tuberculosis.
3.2. Terminalia sericea
The crudemethanol extract of the roots of T. sericea and especially the
n-butanol fraction of this extract gave good growth inhibitory effects
against M. smegmatis showing inhibition zones of 31.5 and 35.5 mm,
respectively and an MIC of 1562 μg/ml for the butanol fraction
(Tables 2 and 3). An aqueous-insoluble part of the root extract gave
Fig. 5. HPLC–UV–DAD chromatograms of a crude methanol extract of Terminalia kaiserana and its fractions obtained using Sephadex LH-20 column chromatography. HPLC-chromatograms
were recorded at 280 nm using the HPLC method I. The crude extract contains several ellagitannins (tR 8.3–22.7min) absent from the Sephadex fractions. The dominating compounds
in fractions 2–4 are ellagic acid and methyl-ellagic acid glycosides (tR 25 and 28min, respectively).
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results are in agreement with York et al. (2012) who demonstrated MIC
values of 670 and 2670μg/ml for an organic solvent and aqueous extract,
respectively, of mature stem bark of T. sericea againstM. smegmatis ATCC
14468.
In contrast to the root extracts, we found that the leaf extracts gave
just slight growth inhibitory effects againstM. smegmatis. The inhibitory
effects of the leaves were concentrated to the butanol-soluble and
chloroform fractions, whereas the aqueous and aqueous-insoluble
extracts did not give any effects (Table 2).
In our earlier investigations T. sericea root and leaf methanolic ex-
tracts gave good effects against several Gram-positive bacteria and
Enterobacter aerogenes (Fyhrquist et al., 2002). Many other authors
have also reported good antibacterial effects of T. sericea leaf, stem
bark and root extracts (Eloff, 1999; Innocent, 2002; Steenkamp et al.,
2004; Moshi and Mbwambo, 2005). Acetone extracts of the stem bark
of T. sericea have been reported to demonstrate good activities against
M. tuberculosis H37 Ra and the multi drug resistant clinical strain Mtb 2
with MIC values of 25 μg/ml (Green et al., 2010), but the active com-
pound (s) in these extracts were not investigated. Eldeen and Van
Staaden (2007) reported good growth inhibitory effects of ethyl acetate,
dichloromethane and ethanol extracts of the roots and stem bark of
T. sericea against Mycobacterium fortuitum (MICs 1560–3120 μg/ml).
There are scanty publications on the chemical structures of antibac-
terial compounds of this plant. Up to date four compoundswith antibac-
terial effects have been isolated from T. sericea roots and stem bark. The
promising antimicrobial compound, anolignan B (Eldeen et al., 2005)
and resveratrol-3-O-β-rutinoside showing some antibacterial activity
(Bombardelli et al., 1975; Joseph et al., 2007) have been characterized
from the stem bark and roots of T. sericea. Termilignan B and arjunicacid, isolated from ethyl acetate extracts of the roots of T. sericea have
given promising antibacterial effects against Gram-positive and
Gram-negative bacteria, but only slight activity against the growth
of Mycobacterium aurum A+ (Eldeen et al., 2008). Therefore, the
antimycobacterially active compounds in the roots of T. sericea
might belong to some other chemical categories than lignans and
pentacyclic triterpenes, or then these compounds possibly act in synergy
in the extracts losing their effects when puriﬁed.
Our preliminary results on the chemical composition of T. sericea roots
obtained using thin layer chromatography on cellulose indicate that the
aqueous and the aqueous-insoluble fractions of a crudemethanol extract
might contain (+)-catechin. The butanol fraction of the crude root
extract might contain epicatechin, epigallocatechin and gallocatechin
(Fig. 3). T. sericea has not been reported to contain catechins before,
although there are some reports on other species of Terminalia containing
this class of compounds. Catechin and epicatechin have been isolated
from the stem bark of a Terminalia mollis (Liu et al., 2009) and
(−)-catechin from the trunk bark of Terminalia glabrescens (Garces
et al., 2003). Catechins have been found to possess interesting antimicro-
bial effects, and for example bactericidal epigallocatechin-gallate was
shown to cause damage to bacterial membranes (Ikigai et al., 1993).
Catechins are also known to inactivate bacterial enzymes (Friedman
et al., 2006). Catechin has been found to give inhibitory effects against
the growth of M. tuberculosis H37Rv showing MIC values of 200 μg/ml,
whereas epigallocatechin was found to be inactive (Martins et al., 2011).
Our HPLC–UV–DAD results show that a butanol fraction of the crude
extract of the roots contains ellagic acid glycosides, ellagitannins, gallic
acid and at least one stilbene (Fig. 4). There are no reports on ellagitannins
or ellagic acid derivates characterized from T. sericea. Ellagitannins might
be responsible for the good antimycobacterial effects of methanol and
Fig. 6.HPLC chromatogram of a methanolic root extract of Terminalia kaiserana recorded at 280 nm using the HPLC method II. According to HPLC-retention times as well as UVλmaxima
data the extract contains gallic acid (tR 1.699min, UVλ absorptionmaxima spectrum inﬁgure), ellagitannins (tR 3.090, 7.504, 7.952, 8.491, 9.819, 10.930, 11.696, 12.491, 15.281 and15.597min)
and ellagic acid glycosides (tR 20.340, 20.510 and 24.207min).
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et al. (2008), lignans and pentacyclic triterpenoids in this plant have
not shown very promising antimycobacterial activity. The good
antimycobacterial activity found by Green et al. (2010) for acetone
extracts of the stem bark of T. sericea may be due to ellagitannins and
ellagic acid glycosides, since this kind of compounds are also extracted
with acetone.
T. sericea is reported to be used for the treatment of tuberculosis in
African traditional medicine (Table 1). In Malawi the fruits are made
into a multi-component treatment for this disease (Msonthi and
Mgombo, 1983). Roots of T. sericea are not reported to be used for the
treatment of TB, but hot water decoctions of the outer layer (bark) of
the roots are used for curation of pneumonia and cough (Drummond
and Coates-Palgrave, 1973). Our results indicate that in addition to the
fruits also the roots of T. sericea could be used for the treatment of
mycobacterial infections.
3.3. Terminalia kaiserana
We report for the ﬁrst time good antimycobacterial activities of both
root and leaf extracts of T. kaiserana. Especially the crude methanol ex-
tract of the roots and its aqueous fraction, enriched in polar ellagitannins,
gave promising results, giving inhibition zones of 27.0 and 25.0mm, re-
spectively and MIC values of 1250 μg/ml for both (Tables 2 and 3). In
addition a BuOH fraction of the leaves gave inhibition zones of 21.0mm
against M. smegmatis (Table 2). Interestingly, also a chloroform-soluble
fraction of the roots, enriched in ellagic acid derivates, gave good
antimycobacterial activities (MIC 1250 μg/ml), thus indicating that
this plant contains antimycobacterially active compounds of a range of
different polarities (Tables 2 and 3).To the best of our knowledge there are no reports on secondary
compounds in T. kaiserana up to date.We have initiatedwork on charac-
terization and isolation of antimicrobial compounds from the root,which
is the most commonly used part of this plant for traditional medicine.
Also preliminary identiﬁcation of compounds in the stem bark has
been performed. According to our results obtained using an acid butanol
test, the roots and stem bark of T. kaiserana contain a high concentration
of condensed tannins, 35.9±0.042 and 48.1±0.272mgg−1, mean±SD,
respectively. For comparison, the total extractable tannin content in
Terminalia brownii leaves was found to be 125 mg g−1 dry weight
(Osuga et al., 2006). It is possible that condensed tannins partly give
the good antimycobacterial effects of both stem bark and root extracts
of T. kaiserana. Some condensed tannins from Terminalia spp. are
known to be very toxic, such as terminalin A, which was isolated from
Terminalia oblongata (Oelrichs et al., 1994). Thus, Terminalia species
have to be used with caution as medicinal plants. Standardized extracts
in which the tannin concentration is controlled, should be developed
for medicinal uses. Condensed tannins are known to give promising
antimicrobial effects against Campylobacter jejuni (Anderson et al.,
2012), Salmonella typhimurium (Costabile et al., 2011) and methicillin-
resistant S. aureus (Hatano et al., 2005), among others, and thus can
form a vital component of the herbal medicine. Condensed tannins
have, to the best of our knowledge, not been screened for activity against
Mycobacterium species.
We also found that the methanolic root extract of T. kaiserana
contains several ellagitannins, ellagic acid glycosides and methylated
ellagic acid glycosides according to HPLC retention times and UVλ
absorbance maxima data (Figs. 5, 6 and 7). The quantitatively most
prominent ellagitannin occurs at tR 15.280 min and has three UV ab-
sorptionmaxima at 216, 256 and 380nm (Figs. 6 and 7). Another tannin
Fig. 7. UVλ absorption maxima spectra of ellagitannins at a) tR= 12.5min and b) tR= 15.2min and c) ellagic acid glycoside at tR= 20.2min in root extracts of Terminalia kaiserana.
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absorption maxima at 217, 258 and 382 nm (Fig. 7). An ellagic acid
glycoside and its isomer occur in high quantities at tR 20.339 and
20.513 min, respectively (Figs. 6 and 7). In an attempt to separate
antimycobacterially active polyphenols and ellagic acid derivates, metha-
nol extracts of the roots of this plant were subjected to Sephadex-LH 20
column chromatography. Nine fractions were pooled together to four
fractions according to RP-18 TLC qualitative data. Especially fractions
F2, F3 and F4 gave good antimycobacterial effects showing MIC values
of 1000 μg/ml, whereas fraction F1 was active only at 4000 μg/ml
(Table 3). According to HPLC–DAD data, fraction F1 contains predomi-
nantly gallotannins and condensed tannins, whereas fractions F2–F4 are
enriched in ellagic acid glycosides, showing two dominating compounds
at tR 25 and 28min, as well as one compound at 26.5min in fraction F4,
using the HPLC method I (Fig. 5). The retention times of peaks at 25 and
28min correspond to those at tR 19.1min (UVλmax=254 and 364 nm,
ellagic acid glycoside) and 22.4 min (UVλmax = 254 and 364 nm,
tentatively identiﬁed as methyl ellagic acid glycoside), when we used
theHPLCmethod II. The compound at tR 26.5min in fraction F4 is possibly
an isomer of compound at tR 25min. Since the ellagic acid glycosides in
fractions F2–F4 are dominating quantitatively, they must be responsible
for the good antimycobacterial effects of these fractions. This data is in
accordance with an investigation of Kuete et al. (2010) who reported
that a methyl derivate of ellagic acid, 3,4′-di-O-methylellagic 3′-O-β-D-
xylopyranoside, isolated from the stem bark of the West African species
T. superba, gives excellent growth inhibitory effects against several
strains ofM. tuberculosis andM. smegmatis.
Ellagic acid as well as its glycosidic derivates is known to possess
antibacterial effects mainly against Gram-positive bacteria (Akiyama
et al., 2001; Soh et al., 2009; Panichayupakaranant et al., 2010) but alsoagainst P. aeruginosa (Sarabhai et al., 2013). Ellagic acid has been
found to inhibit plasma coagulation caused by S. aureus as this bacteria
produce ﬁbrin-rich bioﬁlms to prolong infection (Akiyama et al., 2001).
Ellagic acid-like compounds bind to proteins thus inactivatingmicrobial
adhesions, enzymes, cell membrane transport proteins, etc. (Scalbert,
1991; Haslam, 1996). This warrants further studies on antibacterial
and antimycobacterial ellagic acid derivates and ellagitannins in yet un-
studied species of Terminalia. A number of ellagic acid glycosides have
been isolated from natural sources, but their synthesis is very difﬁcult
due to the O-glycosylation step (Asami et al., 2003). Therefore, higher
plants are the cheapest source of these compounds.
Our results on the good antimycobacterial activity of root and leaf
extracts of T. kaiserana are in accordance with the use of hot water
decoctions of the roots and the leaf sap of this species in African tradi-
tional medicine for treatment of cough, possibly related to tuberculosis
(Table 1; Haerdi, 1964). Moshi et al. (2006) have found that this species
showed cytotoxicity in a brine shrimp test and thus extracts of this plant
should be used with caution in traditional medicine. It would therefore
be important to investigate which component/-s in the extract is/are
toxic and to develop standardized extracts for safer medicinal use.
3.4. Terminalia stenostachya
Crude methanol extracts of fruits and leaves of T. stenostachya
as well as their butanol soluble fractions inhibited the growth of
M. smegmatis. The butanol fractions of the fruits gave the best effects
of the investigated organs showing clear inhibition zones of 35.0 mm
(Table 2). Also the butanol soluble fractions of the leaves gave clear
inhibition zones of 25.0 mm (Table 2). To the best of our knowledge
fruit extracts of T. stenostachya have not been screened before for
Fig. 8.HPLC chromatogram at 280nm of a methanol extract of the leaves of Terminalia stenostachya. HPLCmethod II was used. Gallic acid (tR 1.701min, UVλmax is shown in ﬁgure) concen-
tration is high in the leaves of this species. Ellagitannins (for example compound at tR 10.9min) and gallotannins (compound at tR 13.6min) occur in this extract. Compound at tR 20.608min is
an ellagic acid glycoside which shows two distinct UVλ absorption peaks (shown in ﬁgure).
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bacterial effects of T. stenostachya to date; Mbawambo et al. (2011)
found that stem bark, root and leaf extracts of this species effectively
inhibited the growth of M. madagascariense and M. indicus. In contrast
to the ﬁndings of Mbawambo et al. (2011) we found that a stem bark
extract of this species did not possess signiﬁcant antimycobacterial
activity. This could be due to the use of different test organisms,
M. smegmatis differing in sensitivity toM.madagascariense andM. indicus.
Our preliminary results on the chemical composition of
T. stenostachya, obtained using HPLC–UV–DAD, show that methanolic
leaf extracts contain gallic acid in high concentrations, ellagitannins
and ellagic acid glycosides (Fig. 8). To the best of our knowledge the
chemical composition of T. stenostachya leaves has not been investigated
before.
Root decoctions of T. stenostachya have been reported to be used for
treatment of epilepsy and poisoning in African traditional medicine
(Table 1; Gelﬂand et al., 1985; Neuwinger, 2000) and now our ﬁnding
indicates a new potential use of the leaves and fruits of this plant for
the treatment of mycobacterial infections in East Africa.
3.5. Terminalia spinosa
We found that a crude methanol extract of the leaves of T. spinosa as
well as its butanol soluble fraction gave growth inhibitory effects
against M. smegmatis showing clear inhibition zones with diameters
21.5 and 23.0mm, respectively (Table 2). Extracts of the young twigs
have been found to be inactive against the growth of M. tuberculosis(Fabry et al., 1998) and thus it seems that the leaves contain some
compounds with antimycobacterial activity which are present only
in small concentrations or are absent in the twigs.
We have tentatively identiﬁed gallic acid, gallotannins, ellagitannins
and an ellagic acid glycoside in the leaves of this plant and found that
the leaves are especially rich in different gallotannins (Fig. 9). Tannins
and coumarins have been reported from this plant (Okemo, 1996;
Omulokoli et al., 1997).
T. spinosa is frequently used in African traditional medicine for treat-
ment of malaria, fever, wounds and jaundice (Table 1; Kokwaro, 1976;
Heine and Brenzinger, 1988; Chhabra et al., 1989; Beentje, 1994). The
ways of preparation of T. spinosa for traditional medicine vary. Leaf
juice from pounded leaves is reported to be used as well as teas (Heine
and Brenzinger, 1988) and cold water infusions of the leaves (Beentje,
1994). The cold water infusions and teas extract the gallotannins we
have identiﬁed in the leaves of this plant (Fig. 9). Gallotannins might
give leaf extracts of T. spinosa their good antimycobacterial potential.
Gallotannins, and especially penta- to heptagalloylated gallotannins,
have been shown to potently inhibit the growth of Gram-negative and
Gram-positive bacteria (Tian et al., 2009). Gallotannins have been
found to induce changes in bacterial membrane permeability when
binding to proteins embedded in these membranes (Engels et al.,
2011), and they are able to penetrate bacterialmembranes and coagulate
the cell contents (Li, 2006). Gallotannins bind to enzymes non-
speciﬁcally and thus render them inactive (Konishi et al., 1993). The
inhibition of bacterial growth by gallotannins might also be due to their
ability to complex with metal ions (Scalbert et al., 1999).
Fig. 9. HPLC chromatogram at 280nm of a butanol extract of the leaves of Terminalia spinosa. The HPLC method II was used. This extract contains gallic acid (tR 1.695min), ellagitannins
(compound at tR 10.8min), an ellagic acid derivate (tR 20.627min) and gallotannins (tR 15.0, 17.9, 19,6 and 22.4min). Theﬁgure shows an UV absorption spectrum of themain compound,
a gallotannin at tR 22.412min.
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Due to the increasing incidence of antibiotic resistant tuberculosis,
both globally and in Africa south of Sahara, it would be important to
ﬁnd new and effective medicines against this disease. These antimyco-
bacterially active compounds can be found from higher plants, and
especially from plants which have uses in traditionalmedicine for treat-
ment of tuberculosis and bacterial infections in general.
African species of Terminalia are potential sources of antimyco-
bacterial and antibacterial ellagitannins, ellagic acid derivates, gallotan-
nins and condensed tannins. Species belonging to these genera are often
used as hot water decoctions or water extracts for traditional medicine,
and thus it can be predicted that large amounts of tannins and ellagic
acid glycosides are extracted using these methods of preparation.
Ellagitannins are a group of hydrolyzable tannins which have not been
subjected to thorough investigation on their antimycobacterial potential.
Up to date there exists only one publication on the antimycobacterial
ellagitannin punicalagin, extracted from the stem bark of C. molle
(Asres et al., 2001). Since this group of tannins show a high diversity in
molecular structure it is expected that new antitubercular agents could
be found from this group of secondary metabolites. Von Martius et al.
(2012) found a positive correlation between the total phenolic/tannin
content and antimicrobial activity of Eucalyptus extracts. This can be
true for Terminalia species as well. The relative amounts of hydrolyzable
and condensed tannins did not determine the antimicrobial effects of
Eucalyptus species (Von Martius et al., 2012), but this remains to be
investigated in species of Terminalia. More research would be needed
to determine the individual antimycobacterial and antimicrobial effects
of different kinds of tannins in extracts of Terminalia spp. used in African
traditional medicine.Acknowledgments
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